S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NASDAQ:ICPT

Intercept Pharmaceuticals - ICPT Stock Forecast, Price & News

$14.91
+0.67 (+4.71%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$14.33
$14.95
50-Day Range
$12.91
$17.03
52-Week Range
$10.81
$21.25
Volume
699,310 shs
Average Volume
576,881 shs
Market Capitalization
$617.57 million
P/E Ratio
2.60
Dividend Yield
N/A
Price Target
$25.80

Intercept Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
73.0% Upside
$25.80 Price Target
Short Interest
Bearish
10.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.13
Upright™ Environmental Score
News Sentiment
0.75mentions of Intercept Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.10) to ($2.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

183rd out of 1,043 stocks

Pharmaceutical Preparations Industry

68th out of 510 stocks

ICPT stock logo

About Intercept Pharmaceuticals (NASDAQ:ICPT) Stock

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Stock News Headlines

Intercept updates Phase 3 data for the NASH candidate
Intercept Pharmaceuticals: Trying Times
Expert Ratings for Intercept Pharmaceuticals
Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why
B.Riley Financial Reaffirms Their Buy Rating on Intercept Pharma (ICPT)
See More Headlines
Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Company Calendar

Last Earnings
11/03/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/01/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ICPT
CUSIP
45845P10
Employees
437
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.80
High Stock Price Forecast
$49.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+73.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-91,430,000.00
Pretax Margin
-45.54%

Debt

Sales & Book Value

Annual Sales
$363.47 million
Book Value
$2.60 per share

Miscellaneous

Free Float
31,601,000
Market Cap
$617.57 million
Optionable
Optionable
Beta
1.14

Key Executives

  • Mr. Jerome B. Durso (Age 54)
    Pres, CEO & Director
    Comp: $1.16M
  • Mr. Andrew Saik (Age 53)
    Chief Financial Officer
    Comp: $485.07k
  • Mr. Rocco Venezia (Age 46)
    Chief Accounting Officer & Treasurer
    Comp: $660.62k
  • Mr. Jared M. Freedberg J.D. (Age 54)
    Gen. Counsel
    Comp: $691.46k
  • Dr. M. Michelle Berrey M.D. (Age 55)
    M.P.H., MPH., Pres of R&D and Chief Medical Officer
    Comp: $732.13k
  • Mr. Nareg Sagherian
    Exec. Director of Global Investor Relations
  • Mr. David Ford (Age 52)
    Chief HR Officer
  • Dr. Mark Pruzanski M.D. (Age 54)
    Founder, Advisor & Director
  • Ms. Linda M. Richardson (Age 58)
    Exec. VP & Chief Commercial Officer
  • Paul Nitschmann
    Sr. VP of Regulatory Affairs













ICPT Stock - Frequently Asked Questions

Should I buy or sell Intercept Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICPT shares.
View ICPT analyst ratings
or view top-rated stocks.

What is Intercept Pharmaceuticals' stock price forecast for 2023?

8 Wall Street analysts have issued 12-month price objectives for Intercept Pharmaceuticals' shares. Their ICPT share price forecasts range from $14.00 to $49.00. On average, they anticipate the company's share price to reach $25.80 in the next twelve months. This suggests a possible upside of 73.0% from the stock's current price.
View analysts price targets for ICPT
or view top-rated stocks among Wall Street analysts.

How have ICPT shares performed in 2022?

Intercept Pharmaceuticals' stock was trading at $16.29 at the beginning of the year. Since then, ICPT shares have decreased by 8.5% and is now trading at $14.91.
View the best growth stocks for 2022 here
.

When is Intercept Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our ICPT earnings forecast
.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) issued its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.89. The biopharmaceutical company earned $92.80 million during the quarter, compared to analysts' expectations of $83.04 million. The business's revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($2.01) EPS.

What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?

Intercept Pharmaceuticals issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $340.00 million-$350.00 million, compared to the consensus revenue estimate of $312.94 million.

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?

32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.09%), Vanguard Group Inc. (6.53%), Point72 Asset Management L.P. (3.76%), Jacobs Levy Equity Management Inc. (1.89%), Renaissance Technologies LLC (1.78%) and Macquarie Group Ltd. (1.58%). Insiders that own company stock include Christian Weyer, David A Ford, Gail Cawkwell, Jason Campagna, Mark Pruzanski, Paolo Fundaro, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju.
View institutional ownership trends
.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $14.91.

How much money does Intercept Pharmaceuticals make?

Intercept Pharmaceuticals (NASDAQ:ICPT) has a market capitalization of $617.53 million and generates $363.47 million in revenue each year. The biopharmaceutical company earns $-91,430,000.00 in net income (profit) each year or $5.74 on an earnings per share basis.

How many employees does Intercept Pharmaceuticals have?

The company employs 437 workers across the globe.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The official website for the company is www.interceptpharma.com. The biopharmaceutical company can be reached via phone at (646) 747-1000, via email at investors@interceptpharma.com, or via fax at 646-747-1001.

This page (NASDAQ:ICPT) was last updated on 12/1/2022 by MarketBeat.com Staff